Below are some highlights from first quarter 2022 earnings reports recently released by biologics and biosimilars companies:
Biogen: Last week, Biogen reported total quarterly revenues of $2,532 million, and biosimilar...more
On March 19, 2022, the parties in the Amgen Inc. v. Hospira Inc. (D. Del., No. 20-201) NEULASTA®/pegfilgrastim litigation submitted a stipulation to dismiss all claims and counterclaims in the litigation with prejudice. The...more